Kenvue (KVUE) Stock: Analyst Ratings, Congressional Trades, and Performance

Why this matters: These insights provide a snapshot of Kenvue's financial health and market sentiment, helping investors make informed decisions. Congressional trades can sometimes reflect insider perspectives, while analyst ratings offer a consensus view on the stock's potential.

Kenvue Inc. (NYSE:KVUE) operates as a consumer health company with segments in Self Care, Skin Health and Beauty, and Essential Health. Recent analysis reveals the following:

Analyst Ratings:

Kenvue has received an average recommendation of "Hold" from analysts. Brokerages like UBS Group, JPMorgan Chase & Co., Citigroup, and Canaccord Genuity Group have adjusted their price targets, reflecting varied expectations for the stock's future performance.

Dividend Information:

Kenvue recently declared a quarterly dividend of $0.2075 per share, equating to an annualized dividend of $0.83 and a dividend yield of 4.0%. The dividend was paid on Wednesday, August 27th, to stockholders of record on Wednesday, August 13th.

Stock Performance:

On Monday, KVUE traded down $0.21, hitting $20.33. The stock has a 12-month low of $19.75 and a 12-month high of $25.17. The company’s market capitalization is $39.02 billion, with a P/E ratio of 27.21.

Institutional Ownership:

Hedge funds and institutional investors hold a significant portion of Kenvue's stock. Vanguard Group Inc. and Geode Capital Management LLC have increased their positions, indicating confidence in the company's long-term prospects.

The average recommendation is "Hold."

Kenvue reported $3.84 billion in revenue.

The annualized dividend is $0.83 per share.

Kenvue's stock performance is influenced by analyst ratings, dividend payouts, and institutional investment. Recent data suggests a mixed outlook, with some analysts lowering price targets while others maintain a positive outlook. Keep an eye on future earnings reports and analyst updates to stay informed.

What are your thoughts on Kenvue's future performance? Do you think the analyst ratings accurately reflect the company's potential? Share this article with others who need to stay ahead of this trend!